1,512 results match your criteria: "Center for Liver Diseases[Affiliation]"

Association of Liver Disease and Chronic Pruritus: A Case-Control Study.

Liver Int

October 2024

Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, Miami Itch Center, University of Miami Miller School of Medicine, Miami, Florida, USA.

Article Synopsis
  • * Reverse analysis showed that liver disease patients also reported significantly higher instances of chronic pruritus, indicating a two-way relationship.
  • * Multivariate logistic regression revealed increased odds of specific liver diseases among those with pruritus, particularly hepatitis B and metabolic dysfunction-related liver conditions.
View Article and Find Full Text PDF
Article Synopsis
  • A multicentre study examined the levels of thrombospondin 2 (TSP2) in hepatitis C patients undergoing direct-acting antiviral (DAA) therapy and its potential as a marker for hepatocellular carcinoma (HCC).
  • Results showed that TSP2 levels significantly dropped after DAA treatment, with high levels of TSP2 at the 12-week follow-up linked to a greater risk of developing HCC later on (26.5% vs. 7.0%).
  • Factors like high TSP2 levels, male gender, and a history of HCC were identified as significant predictors for HCC occurrence after treatment, indicating TSP2 could be a valuable biomarker for ongoing monitoring of HCC risk
View Article and Find Full Text PDF
Article Synopsis
  • The study looked at how patients with a liver disease called primary biliary cholangitis (PBC) respond to a treatment called ursodeoxycholic acid (UDCA).
  • It found that many patients (33%) didn’t have a good response after one year, and those who lost their good response had a higher chance of needing a liver transplant or dying.
  • The research showed that staying or getting back to a good response is important for improving long-term health.
View Article and Find Full Text PDF

Integrating biomarkers into a comprehensive strategy is crucial for precise patient management, especially considering the significant healthcare costs associated with diseases. Current studies emphasize the urgent need for a paradigm shift in conceptualizing nonalcoholic fatty liver disease (NAFLD), now renamed metabolic dysfunction-associated steatotic liver disease (MASLD). Biomarkers are emerging as indispensable tools for accurate diagnosis, risk stratification, and monitoring disease progression.

View Article and Find Full Text PDF
Article Synopsis
  • Achieving sustained virologic response (SVR) through direct-acting antivirals lowers the risk of developing hepatocellular carcinoma (HCC), especially in patients with advanced liver conditions like fibrosis or cirrhosis.
  • There are ongoing debates about the best ways to monitor patients post-SVR due to difficulties in accurately staging liver fibrosis and uncertainty about the cost-effectiveness of different surveillance methods.
  • The article reviews current data, discusses the controversies surrounding HCC surveillance, and seeks to offer new insights to improve and standardize monitoring strategies for patients who have cleared hepatitis C virus (HCV).
View Article and Find Full Text PDF
Article Synopsis
  • Resmetirom is the first approved therapy in the US for treating adults with non-cirrhotic nonalcoholic steatohepatitis (NASH) and moderate-to-advanced liver fibrosis, effective as of March 2024.
  • A dynamic population calculator was created to estimate the prevalence of NASH, focusing on those eligible for resmetirom treatment by analyzing various data sources, including health surveys and claims databases.
  • The study estimated that in a population of 1 million, the number of treatment-eligible individuals in the first three years post-approval could range from 1255 to 1699, reflecting a growth rate in diagnoses and treatment eligibility.
View Article and Find Full Text PDF

Electrochemical biosensors for early detection of breast cancer.

Clin Chim Acta

January 2025

Student Research Committee, Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address:

Breast cancer continues to be a significant contributor to global cancer deaths, particularly among women. This highlights the critical role of early detection and treatment in boosting survival rates. While conventional diagnostic methods like mammograms, biopsies, ultrasounds, and MRIs are valuable tools, limitations exist in terms of cost, invasiveness, and the requirement for specialized equipment and trained personnel.

View Article and Find Full Text PDF

Chronic hepatitis B virus (HBV) infection affects about 262 million people worldwide, leading to over 820,000 deaths each year primarily due to cirrhosis and hepatocellular carcinoma. The World Health Organization has pledged to eliminate HBV as a health threat by 2030, but currently, no countries are on track to achieve this goal. One of the barriers to HBV elimination is stigma, causing shame, denial, self-isolation, self-rejection, and depression leading to those with chronic HBV less likely to get tested or seek treatment and more likely to conceal their infection.

View Article and Find Full Text PDF

The epidemiology of Hepatitis B virus (HBV) has drastically changed in recent decades due to public health initiatives, including universal infant vaccination programs,urbanization driving global travel, and migration patterns. Despite screening of pregnant women and newborns significantly reducing the rate of perinatal transmission in certain parts of the world, other, perhaps more uncommon, routes (e.g.

View Article and Find Full Text PDF

Background: Hepatitis C virus (HCV) infection is a systemic disease. However, the relative contribution of intrahepatic and extrahepatic diseases to mediating HCV-induced mortality is unclear, albeit critical in resource allocation for reducing preventable deaths. To this end, this study comprehensively quantified the extent to which intrahepatic and extrahepatic diseases mediate HCV-induced mortality.

View Article and Find Full Text PDF

Background: Alcohol-associated hepatitis (AH) is associated with significant mortality. Model for End-Stage Liver Disease (MELD) score is used to predict short-term mortality and aid in treatment decisions. MELD is frequently updated in the course of AH.

View Article and Find Full Text PDF

Differential Contributions of Fibroblast Subpopulations to Intercellular Communication in Eosinophilic Esophagitis.

Biology (Basel)

June 2024

Swallowing and Esophageal Disorders Center, Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine of USC, Los Angeles, CA 90089, USA.

Fibroblast heterogeneity remains undefined in eosinophilic esophagitis (EoE), an allergic inflammatory disorder complicated by fibrosis. We utilized publicly available single-cell RNA sequencing data (GSE201153) of EoE esophageal biopsies to identify fibroblast sub-populations, related transcriptomes, disease status-specific pathways and cell-cell interactions. IL13-treated fibroblast cultures were used to model active disease.

View Article and Find Full Text PDF

Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis.

Clin Gastroenterol Hepatol

December 2024

Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris; Inserm UMR_S938, Saint-Antoine Research Center, Sorbonne University, Paris, France. Electronic address:

Article Synopsis
  • The study investigates the prognostic value of changes in liver stiffness measurement (LSM) over time in patients with primary biliary cholangitis (PBC) who are being treated with ursodeoxycholic acid.
  • It utilizes data from 3,078 patients over a 19-year period, finding that 59% of participants had an increase in LSM, which is linked to a higher risk of serious clinical events such as cirrhosis complications and liver transplants.
  • The research concludes that monitoring LSM changes provides essential prognostic information, suggesting its potential as a valuable endpoint in clinical trials for PBC treatment.
View Article and Find Full Text PDF

Novel Approach: Maternal TAF Prophylaxis to Prevent HBV Transmission.

Clin Infect Dis

July 2024

Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China.

View Article and Find Full Text PDF
Article Synopsis
  • This phase 1b study assessed the safety and effectiveness of cilofexor, a drug targeting farnesoid X receptors, in patients with compensated cirrhosis caused by primary sclerosing cholangitis over 12 weeks.
  • Patients received increasing doses of cilofexor, and while most reported side effects like pruritus and fatigue, there were no serious adverse events.
  • Results showed significant improvements in liver function markers, indicating that cilofexor may help manage cholestasis in these patients.
View Article and Find Full Text PDF

Hepatic fibrosis (HF) is a pathological process of structural and functional impairment of the liver and is a key component in the progression of chronic liver disease. There are no specific anti-hepatic fibrosis (anti-HF) drugs, and HF can only be improved or prevented by alleviating the cause. Autophagy of hepatic stellate cells (HSCs) is closely related to the development of HF.

View Article and Find Full Text PDF

Background: Better access to direct-acting antiviral (DAA) therapy has broadened the utilization of hepatitis C virus (HCV) nucleic acid testing (NAT) positive organs with excellent outcomes. However, DAA therapy has been associated with hepatitis B virus (HBV) reactivation.

Aim: To determine the risk of HBV transmission or reactivation with utilization of HBV core antibody positive (HBcAb+) and HCV NAT positive (HCV+) organs, which presumably required DAA therapy.

View Article and Find Full Text PDF

Histological subtyping of hepatocellular carcinoma (HCC) is challenging in the presence of histological heterogeneity, where distinctly different morphological patterns are present within the same tumor. Current approaches rely on percent cut-offs. We hypothesized that morphologic intratumor heterogeneity is a non-random biological feature and that incorporating recurrent patterns would improve histological subtyping of HCC.

View Article and Find Full Text PDF

SH-Alb inhibits phenotype remodeling of pro-fibrotic macrophage to attenuate liver fibrosis through SIRT3-SOD2 axis.

Biomed Pharmacother

July 2024

Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, PR China; Shandong Provincial Engineering and Technological Research Center for Liver Diseases Prevention and Control, Jinan, Shandong 250021, PR China. Electronic address:

Albumin has a variety of biological functions, such as immunomodulatory and antioxidant activity, which depends largely on its thiol activity. However, in clinical trials, the treatment of albumin by injection of commercial human serum albumin (HSA) did not achieve the desired results. Here, we constructed reduced modified albumin (SH-Alb) for in vivo and in vitro experiments to investigate the reasons why HSA did not achieve the expected effects.

View Article and Find Full Text PDF

The mitochondrial TSPO ligand Atriol mitigates metabolic-associated steatohepatitis by downregulating CXCL1.

Metabolism

October 2024

Department of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90089, USA. Electronic address:

Article Synopsis
  • The study looked at a protein called TSPO that helps move cholesterol in mitochondria, and Atriol is a substance that can stop TSPO from binding to cholesterol.
  • Researchers found that Atriol can help improve a liver disease called MASH by fixing mitochondrial function and reducing inflammation.
  • In tests on rats with MASH, Atriol helped reduce fat buildup, inflammation, and other harmful effects, showing it might be a helpful treatment for this liver condition.
View Article and Find Full Text PDF